MedTrace Logo

S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer

NCT03316326 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-10-20

No results posted yet for this study

Summary

This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design. After 4 cycles of SIROX regimen, patients will proceed to curative resection.

Conditions

Interventions

DRUG

Tegafur-gimeracil-oteracil potassium

40 mg bid, D1-14

DRUG

Oxaliplatin

85 mg/m2, D1

DRUG

Irinotecan

150 mg/m2, D8

Sponsors & Collaborators

  • TTY Biopharm

    collaborator INDUSTRY

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yu-Wen Tien, M.D., Ph. D. · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2021-12-31
Completion
2021-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316326 on ClinicalTrials.gov